-7%

est. 2Y upside i

HealthcareSeries A

Rank

#3091

Sector

Healthcare / Fertility Services

Est. Liquidity

~3Y

Data Quality

Data: Low

Weak pass.

Last updated: July 3, 2026

Bull (10%)+180%

Pluro achieves rapid clinic consolidation and category leadership, driving a 3x valuation to $336M, supported by IPO window and Bessemer backing. After 20% dilution from future raise, net upside for common is 180%.

Base (50%)+30%

Steady clinic additions and moderate growth lead to slight valuation appreciation to $145M, but public market comparisons imply limited multiple expansion. After dilution, net upside is 30%.

Bear (40%)-100%

Incumbent chains like Indira IVF dominate, partner clinics churn, and funding dries up. Implied exit value falls below total funding ($14.1M), wiping out common equity entirely.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Funding Intensity

1260%

Total funding of $14.1M against $112M valuation implies 12.6% preferred overhang, which is moderate but protective for exit below $112M.

Dilution Risk

moderate

Likely follow-on rounds within 18 months assumed at 20% dilution; no anti-dilution provisions mentioned.

Secondary Liquidity

none

No secondary market evidenced; common stock is illiquid until exit (M&A/IPO).

Questions to Ask at the Interview

Strategic questions based on Pluro's data — designed to show you've done your homework.

  • 1

    “How does Pluro's asset-light partnership model compete on cost and quality vs. capital-intensive chains like Indira IVF?”

  • 2

    “What is the current revenue run-rate and path to profitability given the M&A timeline?”

  • 3

    “Given the high preference overhang (12.6%), how does equity upside for early non-employee participants compare to later rounds?”

Community

Valuation Sentiment

Our model estimates -7% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.